Welcome to our dedicated page for Vallon Pharmaceuticals news (Ticker: VLON), a resource for investors and traders seeking the latest updates and insights on Vallon Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vallon Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vallon Pharmaceuticals's position in the market.
Vallon Pharmaceuticals (NASDAQ: VLON) reported additional results from its SEAL study on ADAIR, its abuse-deterrent formulation of dextroamphetamine aimed at treating ADHD and narcolepsy. The study revealed ADAIR's lower pharmacokinetic profile compared to crushed dextroamphetamine, with significantly lower scores on drug liking and willingness to use again. Despite not meeting its primary endpoint for drug liking, Vallon sees potential in secondary outcomes. The company is also exploring strategic alternatives to maximize shareholder value while streamlining operations.
Vallon Pharmaceuticals (NASDAQ: VLON) announced that the Japan Patent Office granted Patent No. 7054709 for its ADAIR product, an abuse-deterrent formulation of immediate-release dextroamphetamine. This patent covers composition and manufacturing methods, extending its base patent term until 2038. Vallon’s CEO noted the growing Japanese market for ADHD medications, highlighting ADAIR's potential as a safe option. The company is also exploring strategic alternatives to maximize shareholder value, which could lead to a merger or acquisition.
Vallon Pharmaceuticals (NASDAQ: VLON) reported its Q1 financial results, highlighting a net loss of $2.6 million. The SEAL study for its ADAIR product did not meet its primary endpoint, raising concerns over its development. Vallon is currently engaged in a strategic review process to evaluate options, including possible mergers or acquisitions, with the goal of maximizing shareholder value. The company has $5.2 million in cash and equivalents as of March 31, 2022.
Vallon Pharmaceuticals (NASDAQ: VLON) announced its engagement with Ladenburg Thalmann & Co. Inc. to explore strategic alternatives aimed at maximizing shareholder value. This review may include potential mergers, investments, or acquisitions. Concurrently, Vallon is assessing its operations for ADAIR and ADMIR, both abuse-deterrent formulations for treating ADHD and narcolepsy. The company is also streamlining operations to preserve capital. No specific transactions are guaranteed, and further details will be disclosed only upon engaging in a specific deal.
Vallon Pharmaceuticals (NASDAQ: VLON) announced that its President and CEO, David Baker, will participate in the Advances in Neuropsychiatry panel at the 5th Annual Neuroscience Innovation Forum on March 23, 2022, at 9:00 AM ET.
The event will feature a live webcast accessible to registered attendees, emphasizing Vallon's focus on developing medications to treat CNS disorders. Their lead candidate, ADAIR, is an abuse-deterrent formulation of amphetamine aimed at treating ADHD and narcolepsy.
Vallon Pharmaceuticals released topline results from the pivotal SEAL study on its abuse-deterrent formulation, ADAIR, for ADHD treatment. The study did not meet its primary endpoint of Emax Drug Liking compared to dextroamphetamine, although secondary pharmacodynamic endpoints showed statistical significance. ADAIR was well tolerated with no serious adverse events. Vallon aims to analyze further results and plans to request a formal meeting with the FDA for future development steps.
Vallon Pharmaceuticals has appointed Meenu Karson to its Board of Directors. With over 15 years of experience in biopharmaceuticals, Karson has a strong track record in capital markets and strategic leadership. She previously served as President and CEO of Proteostasis Therapeutics, where she raised over $300 million and facilitated pivotal partnerships. Vallon focuses on developing abuse-deterrent drugs for CNS disorders, with its lead product candidate, ADAIR, aimed at treating ADHD and narcolepsy. The company anticipates significant milestones in its ongoing development programs.
Vallon Pharmaceuticals (NASDAQ: VLON) announced the issuance of U.S. patent No. 11,253,490 for its investigational abuse-deterrent formulation, ADAIR, designed to treat cognitive impairment linked to COVID-19.
The patent extends until 2041, covering ADAIR's use for alleviating symptoms often termed 'COVID brain fog.' Vallon is engaged in discussions with a major academic research center for a proof-of-concept study on ADAIR's efficacy.
ADAIR, an investigational drug, aims to mitigate cognitive issues in recovering COVID-19 patients, highlighting a significant market opportunity.
Vallon Pharmaceuticals reported its 2021 financial results, showing a net loss of $9.3 million, up from $4.8 million in 2020. The company is advancing its pivotal ADAIR study with topline data expected this quarter and plans to commence a first-in-human trial for its ADMIR program in 2022. With $7.5 million in cash, Vallon aims to address the growing need for abuse-deterrent formulations in the CNS disorder market, particularly for ADHD treatments. CEO David Baker highlighted the potential of their platform technology to deliver shareholder value.
Vallon Pharmaceuticals (NASDAQ: VLON) announced that CEO David Baker will present at the Virtual Investor 2022 Top Picks Conference on January 25, 2022, at 9:00 AM ET. The event will include a presentation, moderated discussion, and interactive Q&A, allowing investors to submit questions live or in advance. A live webcast will be available, with a replay accessible post-event.
